Peking University First Hospital

Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy

Phase 2/3Recruiting202690 people6 Oct 2026clinicaltrials.gov

NCT07717242

CollaboratorPhase 2Recruiting202680 people21 Jul 2026clinicaltrials.gov

NCT07693036

Phase 1/2Recruiting202666 people9 Jul 2026clinicaltrials.gov

NCT07165158

CollaboratorPhase 4Not yet recruiting2025150 people10 Sept 2025clinicaltrials.gov

NCT06722586

Phase 4Recruiting202584 people9 Dec 2024clinicaltrials.gov

NCT06176235

CollaboratorPhase 2Withdrawn20230 people19 Dec 2023clinicaltrials.gov

NCT05932524

CollaboratorPhase 2Status unknown2023132 people6 Jul 2023clinicaltrials.gov

NCT05844813

CollaboratorPhase 4Enrolling by invitation2022102 people6 May 2023clinicaltrials.gov

NCT05702905

Phase 4Status unknown202375 people27 Jan 2023clinicaltrials.gov

NCT05655728

Phase 4Status unknown202378 people19 Dec 2022clinicaltrials.gov

NCT05386186

CollaboratorPhase 4Status unknown2022192 people23 May 2022clinicaltrials.gov

NCT04974151

CollaboratorPhase 4Recruiting202424,000 people23 Jul 2021clinicaltrials.gov

NCT04974138

CollaboratorPhase 4Recruiting202432,000 people23 Jul 2021clinicaltrials.gov

NCT04848454

Phase 2Status unknown202130 people19 Apr 2021clinicaltrials.gov

NCT04025840

Phase 4Active, not recruiting2019260 people19 Jul 2019clinicaltrials.gov

NCT03764787

Phase 1/2Status unknown201930 people5 Dec 2018clinicaltrials.gov

NCT03472508

CollaboratorPhase 4Status unknown20183,600 people21 Mar 2018clinicaltrials.gov

NCT03264625

Phase 2Completed201760 people29 Aug 2017clinicaltrials.gov

NCT03200600

Phase 4Terminated2017126 people27 Jun 2017clinicaltrials.gov

NCT03172988

Phase 4Terminated2017126 people1 Jun 2017clinicaltrials.gov